Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Inhaled GM-CSF in Idiopathic Pulmonary Alveolar Proteinosis
jRCT1091220013Phase 2Completed
- Sponsor
- Bioscience Medical Research Center, Niigata University
- Start
- Aug 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of granulocyte macrophage-colony stimulating factor in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Bioscience Medical Research Center, Niigata University. Primary endpoint: Alveolar-arterial oxygen difference improvement at Week 24. Started Aug 2007; status: completed.
02
Drugs
granulocyte macrophage-colony stimulating factor
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on jRCT1091220013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220013.